Compare XTNT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | CRDL |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 97.3M |
| IPO Year | 2009 | 2017 |
| Metric | XTNT | CRDL |
|---|---|---|
| Price | $0.58 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.50 | ★ $9.00 |
| AVG Volume (30 Days) | 153.6K | ★ 354.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.77 |
| 52 Week High | $0.95 | $1.59 |
| Indicator | XTNT | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 45.34 |
| Support Level | $0.55 | $0.94 |
| Resistance Level | $0.68 | $1.09 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 29.09 | 24.54 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.